Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Protein That Suppresses Invadopodia Formation Prevents Spread of Breast Cancer Cells

By LabMedica International staff writers
Posted on 17 May 2011
Elevated activity of the adaptor protein Cdc42-interacting protein 4 (CIP4) has been found to suppress the formation of invadopodia, actin-rich membrane protrusions that promote extracellular matrix (ECM) degradation and invasiveness of tumor cells.

Investigators at Queen's University (Kingston, ON, Canada) demonstrated the role of CIP4 by using RNA interference technology to block its activity in cultures of breast tumor cells.

They reported in the May 15, 2011, issue of the Journal of Cell Science that these CIP4 "knockdown” cells degraded more ECM, had increased numbers of mature invadopodia, and were more invasive through matrigel. More...
The inhibitory role of CIP4 was explained by the finding that CIP4 limited surface expression of transmembrane type I matrix metalloprotease (MT1-MMP), by promoting MT1-MMP internalization. By removing this enzyme complex from the cell surface CIP4 suppressed invadopodia formation and reduced the ability of the cancer cells to metastasize.

"Cancer researchers want to design new therapeutic strategies in which the metastasis or spreading stage of cancer can be blocked,” explained senior author Dr. Andrew Craig, professor of biochemistry and cancer research at Queen's University. "Patients stand a much better chance of survival if the primary tumor is the only tumor that needs to be treated.”

Related Links:
Queen's University



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.